this company's valuation is blasphemy

EXAS just under doubled revenue from 2019 to 2020 and is trading at 2019 levels
HUH????
a biotech company with a positive EBITDA not crazy multiples and a testing kit that does not need FDA approval
it is clearly working look at revenue growth, and before you talk about the loss relax they have tons of cash
second biggest ARKG holding and a two-ish year bullflag
i think the breakout of this one will lead to a big bull to the high $100's and the low 200s
it'll take a while I'm not trading it I'm investing in it
also oscellator looks like it's at a bottom and at the 200 ema